<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of thrombopoietin (TPO) on cell proliferation and differentiation, and the relation between these effects and the expression of c-mpl on <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells were studied in seven <z:hpo ids='HP_0011009'>acute</z:hpo> myelogeneous <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines and seven myelogeneous blast cell preparations from patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPDs</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Among the <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells, five preparations of megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells from patients and one megakaryoblastic cell line, CMK 11.5, proliferated in response to TPO in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>CMK 11.5 and the blastic cells from one patient diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> differentiated with increasing expression of CD41a in response to TPO </plain></SENT>
<SENT sid="3" pm="."><plain>However, TPO had no effect on the cells lacking megakaryocytic characteristics </plain></SENT>
<SENT sid="4" pm="."><plain>Some patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> develop <z:hpo ids='HP_0011009'>acute</z:hpo> transformation with blasts demonstrating megakaryocytic features, and some of these cells show growth in response to TPO </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, in vivo administration of TPO should be considered carefully for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, since TPO may induce leukemic cell proliferation </plain></SENT>
</text></document>